Low-dose Bevacizumab With HSRT vs BVZ Alone for GBM at First Recurrence
Status:
Active, not recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This randomized phase II trial studies how well lose dose bevacizumab with Hypofractionated
Stereotactic Radiotherapy (HSRT) works versus bevacizumab alone in treating patients with
glioblastoma at first recurrence. The primary endpoint is 6-month progress-free
survivaloverall survival after the treatment. Secondary endpoints included overall survival,
objective response rate, cognitive function, quality of life and toxicity.